Charles J. Homcy - 30 Jan 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
Director
Signature
/s/ Courtney Phillips, as attorney-in-fact
Issuer symbol
MAZE
Transactions as of
30 Jan 2025
Net transactions value
$0
Form type
3
Filing time
30 Jan 2025, 16:31:51 UTC
Previous filing
25 Jun 2024
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MAZE Common Stock 28,523 30 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MAZE Series B Preferred Stock 30 Jan 2025 Common Stock 72,727 Direct F1
holding MAZE Series C Preferred Stock 30 Jan 2025 Common Stock 169,405 Direct F2
holding MAZE Series D-1 Preferred Stock 30 Jan 2025 Common Stock 71,564 By Trust F3, F4
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 80,385 $10.42 Direct F5
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 5,704 $10.42 Direct F6
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 46,675 $10.42 Direct F7
holding MAZE Stock Option (Right to Buy) 30 Jan 2025 Common Stock 45,638 $10.42 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series B Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date.
F2 Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series C Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date.
F3 Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series D-1 Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.
F4 These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is the trustee.
F5 The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2024.
F6 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F7 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F8 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.